The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology（2023）
摘要
MAFLD was a beneficial factor for survival in patients with HCC treated with lenvatinib. Moreover, the better OS of the MAFLD group was more pronounced in patients with non-viral HCC. Lenvatinib may be a suitable agent for patients with non-viral HCC and MAFLD.
更多查看译文
关键词
hepatocellular carcinoma,lenvatinib,metabolic dysfunction-associated fatty liver disease,non-viral hepatoma,survival
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要